ArticleBlood advances2021

A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.

David J DiLillo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.